risk of non-Hodgkin lymphoma A prospective study of 67 serum immune and inflammation markers and

http://bloodjournal.hematologylibrary.org/content/122/6/951.full.html Updated information and services can be found at: (1485 articles) Lymphoid Neoplasia • Articles on similar topics can be found in the following Blood collections http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#repub_requests Information about reproducing this article in parts or in its entirety may be found online at: http://bloodjournal.hematologylibrary.org/site/misc/rights.xhtml#reprints Information about ordering reprints may be found online at: http://bloodjournal.hematologylibrary.org/site/subscriptions/index.xhtml Information about subscriptions and ASH membership may be found online at:

[1]  A. LaCroix,et al.  Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. , 2012, Cancer research.

[2]  N. Rothman,et al.  Circulating Soluble CD30 and Future Risk of Lymphoma; Evidence from Two Prospective Studies in the General Population , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[3]  N. Rothman,et al.  Prediagnostic serum levels of cytokines and other immune markers and risk of non-hodgkin lymphoma. , 2011, Cancer research.

[4]  J. P. McCoy,et al.  Evaluation of Multiplexed Cytokine and Inflammation Marker Measurements: a Methodologic Study , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[5]  R. Detels,et al.  Expression and Function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma , 2010, AIDS research and treatment.

[6]  Miriam Davis,et al.  TNF receptor 2 pathway: drug target for autoimmune diseases , 2010, Nature Reviews Drug Discovery.

[7]  P. Vineis,et al.  Plasma Cytokines and Future Risk of Non-Hodgkin Lymphoma (NHL): A Case-Control Study Nested in the Italian European Prospective Investigation into Cancer and Nutrition , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[8]  Mengling Liu,et al.  Circulating cytokines and risk of B-cell non-Hodgkin lymphoma: a prospective study , 2010, Cancer Causes & Control.

[9]  J. Cerhan,et al.  Tumor necrosis factor (TNF) and lymphotoxin-alpha (LTA) polymorphisms and risk of non-Hodgkin lymphoma in the InterLymph Consortium. , 2010, American journal of epidemiology.

[10]  M. Fujita,et al.  Soluble VEGF receptor-2 is increased in sera of subjects with metabolic syndrome in association with insulin resistance. , 2010, Atherosclerosis.

[11]  N. Rothman,et al.  A prospective study of serum soluble CD30 concentration and risk of non-Hodgkin lymphoma. , 2009, Blood.

[12]  Ya-xi Zhang,et al.  TRAIL receptor mediates inflammatory cytokine release in an NF-κB-dependent manner , 2009, Cell Research.

[13]  C. Chao,et al.  Type 2 diabetes mellitus and risk of non-Hodgkin lymphoma: a systematic review and meta-analysis. , 2008, American journal of epidemiology.

[14]  M. Keating,et al.  Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. , 2007, Blood.

[15]  D. Weisenburger,et al.  Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). , 2007, Blood.

[16]  J. Ruland,et al.  Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. , 2007, Blood.

[17]  D. Kyriakou,et al.  Angiogenesis‐related growth factors and cytokines in the serum of patients with B non‐Hodgkin lymphoma; relation to clinical features and response to treatment , 2007, International journal of laboratory hematology.

[18]  F. Tas,et al.  Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients , 2006, Melanoma research.

[19]  K. Do,et al.  Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia. , 2005, Blood.

[20]  Markus Schilhabel,et al.  Characterization of 8p21.3 chromosomal deletions in B-cell lymphoma: TRAIL-R1 and TRAIL-R2 as candidate dosage-dependent tumor suppressor genes. , 2005, Blood.

[21]  S. Aref,et al.  Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come. , 2005, Hematology.

[22]  J. Cooke,et al.  Adenoviral Gene Transfer With Soluble Vascular Endothelial Growth Factor Receptors Impairs Angiogenesis and Perfusion in a Murine Model of Hindlimb Ischemia , 2004, Circulation.

[23]  J. Tschopp,et al.  TNF Deficiency Fails to Protect BAFF Transgenic Mice against Autoimmunity and Reveals a Predisposition to B Cell Lymphoma1 , 2004, The Journal of Immunology.

[24]  Paolo Ghia,et al.  CXCL13 (BCA‐1) is produced by follicular lymphoma cells: role in the accumulation of malignant B cells , 2002, British journal of haematology.

[25]  M. Shibuya.  Structure and dual function of vascular endothelial growth factor receptor-1 (Flt-1). , 2001, The international journal of biochemistry & cell biology.

[26]  J. Gohagan,et al.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.

[27]  J. Gohagan,et al.  Etiologic and early marker studies in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. , 2000, Controlled clinical trials.

[28]  R. Kurth,et al.  Interleukin‐16 stimulates the expression and production of pro‐inflammatory cytokines by human monocytes , 2000, Immunology.

[29]  M. Baggiolini,et al.  B Cell–attracting Chemokine 1, a Human CXC Chemokine Expressed in Lymphoid Tissues, Selectively Attracts B Lymphocytes via BLR1/CXCR5 , 1998, The Journal of experimental medicine.

[30]  M. Brockhaus.  Soluble TNF receptor: what is the significance? , 1997, Intensive Care Medicine.

[31]  G. Pacini,et al.  Amylin: History and Overview , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[32]  D. Wallach,et al.  Variation in serum levels of the soluble TNF receptors among healthy individuals. , 1992, Lymphokine and cytokine research.

[33]  H. Schoenfeld,et al.  Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies. , 1990, Proceedings of the National Academy of Sciences of the United States of America.